Ovariekreft

Heterogenitet i ovariekreft - identifisering av kliniske biomarkørerHeterogeneity in Ovarian Cancer - Identification of Clinical Biomarkers

Ovarian Cancer is the most lethal gynecological cancer. The symptoms of ovarian cancer come late and are often non-specific. Consequently, approximately two-thirds of the patients are diagnosed with advanced stages (FIGO stage III or IV). Patients with local disease stage at diagnosis have a 5-year survival of about 80-90%, whereas for stage III and IV patients, the survival is about 30% and 15%, respectively.

Denne meldingen er dessverre ikke tilgjengelig på norsk.

NCGC Intranett